Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines

Molecular Cancer Therapeutics

Volumn 7, Issue 10, 2008, Pages 3123-3128

  Lorenzi, Philip L ^a   Llamas, Jenny ^a   Gunsior, Michele ^a   Ozbun, Laurent ^a   Reinhold, William C ^a   Varma, Sudhir ^a   Ji, Helen ^a   Kim, Hijoo ^a   Hutchinson, Amy A ^b   Kohn, Elise C ^a   Goldsmith, Paul K ^a   Birrer, Michael J ^a   Weinstein, John N ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; ASPARTATE AMMONIA LIGASE; BIOLOGICAL MARKER; MESSENGER RNA; TUMOR MARKER;

ARTICLE; CANCER CELL CULTURE; CHEMOLUMINESCENCE; DNA DETERMINATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOASSAY; MICROARRAY ANALYSIS; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ANALYSIS; RNA INTERFERENCE; DNA FINGERPRINTING; DNA MICROARRAY; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OVARY TUMOR; TUMOR CELL LINE;

ASPARAGINASE; ASPARTATE-AMMONIA LIGASE; CELL LINE, TUMOR; DNA FINGERPRINTING; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 55749114384     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0589     Document Type: Article

References (13)

1. American Cancer Society [homepage on the Internet]. Atlanta: American Cancer Society; 2000-2008 [cited 2008 Aug 1]. Available from: http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf.
2. Lorenzi PL, Reinhold WC, Rudelius M, et al. Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther 2006;5:2613-23.
3. Manzano RG, Montuenga LM, Dayton M, et al. CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential. Oncogene 2002;21:4435-47.
4. Schilder RJ, Hall L, Monks A, et al. Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer 1990;45: 416-22.
5. Donninger H, Bonome T, Radonovich M, et al. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene 2004;23:8065-77.
6. Bussey KJ, Chin K, Lababidi S, et al. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther 2006;5:853-67.
7. Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24:236-44.
8. Fine BM, Kaspers GJ, Ho M, Loonen AH, Boxer LM. A genome-wide view of the in vitro response to L-asparaginase in acute lymphoblastic leukemia. Cancer Res 2005;65:291-9.
9. Hutson RG, Kitoh T, Moraga Amador DA, Cosic S, Schuster SM, Kilberg MS. Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells. Am J Physiol 1997;272: C1691-9.
10. Su N, Pan YX, Zhou M, Harvey RC, Hunger SP, Kilberg MS. Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines. Pediatr Blood Cancer 2007;50:274-9.
11. Stams WA, den Boer ML, Beverloo HB, et al. Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. Blood 2003;101: 2743-7.
12. Reddy GK. Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer. Clin Lung Cancer 2005;7:163-5.
13. Rosell R, Ichinose Y, Taron M, et al. Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. Lung Cancer 2005;50:25-33.